|
[1]
|
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome[J]. Lancet, 2005, 365:1415-1428. doi: 10.1016/S0140-6736(05)66378-7 |
|
[2]
|
Tschopp J, Martinon F, Burns K. NALPs:a novel protein family involved in inflammation[J]. Nat Rev Mol Cell Biol, 2003, 4:95-104. doi: 10.1038/nrm1019 |
|
[3]
|
Fritz JH, Ferrero RL, Philpott DJ, et al. Nod-like proteins in immunity, inflammation and disease[J]. Nat Immunol, 2006, 7:1250-1257. doi: 10.1038/ni1412 |
|
[4]
|
Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes[J]. Nat Rev Immunol, 2013, 13:397-411. doi: 10.1038/nri3452 |
|
[5]
|
Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation[J]. Nat Immunol, 2010, 11:136-140. doi: 10.1038/ni.1831 |
|
[6]
|
Kanneganti TD, Dixit VD. Immunological complications of obesity[J]. Nat Immunol, 2012, 13:707-712. doi: 10.1038/ni.2343 |
|
[7]
|
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease[J]. Nat Rev Immunol, 2011, 11:98-107. doi: 10.1038/nri2925 |
|
[8]
|
Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases[J]. Nat Rev Immunol, 2008, 8:923-934. doi: 10.1038/nri2449 |
|
[9]
|
Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance[J]. Nat Med, 2011, 17:179-188. doi: 10.1038/nm.2279 |
|
[10]
|
Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling[J]. Nat Immunol, 2011, 12:408-415. doi: 10.1038/ni.2022 |
|
[11]
|
Stienstra R, Joosten LAB, Koenen T, et al. The Inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity[J]. Cell Metab, 2010, 12:593-605. doi: 10.1016/j.cmet.2010.11.011 |
|
[12]
|
Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes[J]. Nat Immunol, 2010, 11:897-904. doi: 10.1038/ni.1935 |
|
[13]
|
Koenen TB, Stienstra R, van Tits LJ, et al. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1 beta transcription in human adipose tissue[J]. Diabetes, 2011, 60:517-524. doi: 10.2337/db10-0266 |
|
[14]
|
Jager J, Gremeaux T, Cormont M, et al. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression[J]. Endocrinology, 2007, 148:241-251. doi: 10.1210/en.2006-0692 |
|
[15]
|
Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes:results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study[J]. Diabetes, 2003, 52:812-817. doi: 10.2337/diabetes.52.3.812 |
|
[16]
|
Malozowski S, Sahlroot JT. Interleukin-1-receptor antagonist in type 2 diabetes mellitus[J]. N Engl J Med, 2007, 357:302-303. doi: 10.1056/NEJMc071324 |
|
[17]
|
Akash MS, Shen Q, Rehman K, et al. Interleukin-1 receptor antagonist:a new therapy for type 2 diabetes mellitus[J]. J Pharm Sci, 2012, 101:1647-1658. doi: 10.1002/jps.23057 |
|
[18]
|
Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen:a phase IIb randomized, placebo-controlled trial[J]. Circulation, 2012, 126:2739-2748. doi: 10.1161/CIRCULATIONAHA.112.122556 |
|
[19]
|
Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes[J]. Diabetes Care, 2012, 35:1654-1662. doi: 10.2337/dc11-2219 |
|
[20]
|
Sloan-Lancaster J, Abu-Raddad E, Polzer J, et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes[J]. Diabetes Care, 2013, 36:2239-2246. doi: 10.2337/dc12-1835 |
|
[21]
|
Rotter V, Nagaev I, Smith U. Interleukin-6(IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects[J]. J Biol Chem, 2003, 278:45777-45784. doi: 10.1074/jbc.M301977200 |
|
[22]
|
Senn JJ, Klover PJ, Nowak IA, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes[J]. Diabetes, 2002, 51:3391-3399. doi: 10.2337/diabetes.51.12.3391 |
|
[23]
|
Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3(SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes[J]. J Biol Chem, 2003, 278:13740-13746. doi: 10.1074/jbc.M210689200 |
|
[24]
|
Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss[J]. J Clin Endocrinol Metab, 2000, 85:3338-3342. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5217e7a390c760f0d19146061dd825f9 |
|
[25]
|
Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes:a systematic review and meta-analysis[J]. Diabetes Care, 2013, 36:166-175. doi: 10.2337/dc12-0702 |
|
[26]
|
Hotamisligil GS, Budavari A, Murray D, et al. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha[J]. J Clin Invest, 1994, 94:1543-1549. doi: 10.1172/JCI117495 |
|
[27]
|
Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase[J]. J Clin Invest, 1995, 95:2111-2119. doi: 10.1172/JCI117899 |
|
[28]
|
Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year[J]. Circulation, 2002, 105:804-809. doi: 10.1161/hc0702.104279 |
|
[29]
|
Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance[J]. J Clin Endocrinol Metab, 2008, 93:3165-3172. doi: 10.1210/jc.2008-0425 |
|
[30]
|
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization[J]. J Clin Invest, 2007, 117:175-184. doi: 10.1172/JCI29881 |
|
[31]
|
Lee HM, Kim JJ, Kim HJ, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes[J]. Diabetes, 2013, 62:194-204. doi: 10.2337/db12-0420 |
|
[32]
|
Zheng Y, Zhang D, Zhang L, et al. Variants of NLRP3 gene are associated with insulin resistance in Chinese Han population with type-2 diabetes[J]. Gene, 2013, 530:151-154. doi: 10.1016/j.gene.2013.07.082 |
|
[33]
|
Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in > 80000 subjects identifies multiple loci for C-reactive protein levels[J]. Circulation, 2011, 123:731-738. doi: 10.1161/CIRCULATIONAHA.110.948570 |
|
[34]
|
Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome[J]. J Cell Biol, 2009, 187:61-70. doi: 10.1083/jcb.200903124 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
